Mitochondrial DNA (mtDNA) accumulates mutations with aging in human beings and animal models of accelerated mtDNA mutagenesis produce advanced aging phenotypes such as osteoporosis, cardiomyopathy, neurodegeneration, hair loss, anemia and reduced fertility. Though compelling, these animal models are insufficient to prove that mtDNA is responsible for aging phenotypes. If mtDNA could be delivered to mitochondria in vivo, the role of mtDNA in aging could be directly addressed. In conjunction with the Center for the Study of Neurodegenerative Disease (CSND) at the University of Virginia, in a Phase I STTR, Gencia Corporation successfully utilized a method to transfect mitochondria with full-length mtDNA. This was done by using a novel mitochondrial transfection technology, Protofection? (Protein Mediated Transfection), a technology developed and solely owned by Gencia Corporation. Protofection is a DNA-binding, non-viral delivery vector consisting of an engineered recombinant protein that targets mitochondria for DNA delivery. Additional data beyond the aims of the Phase I study show that protofection can deliver and express a full-length mtDNA engineered to express a reporter protein (GFP, Green Fluorescent Protein), in vivo and that delivery of normal mtDNA can ameliorate metabolic defects in cytoplasmic hybrid (cybrid) cells made from aged human subjects. The mechanism by which the mitochondrial transfection technology delivers mtDNA to mitochondria was also discovered and suggests the existence of mitochondrial lipid rafts. In this Phase II STTR, Gencia Corporation and the CSND propose to address the contribution of mitochondrial genomic damage to aging phenotypes by transfecting normal mtDNA into aged mice and mtDNA from aged mice into young mice. The proposed mtDNA transfection experiments will directly determine which aspects of aging phenotypes are caused by mtDNA and which can be reversed by the delivery of normal mtDNA. Efficacy in ameliorating specific phenotypes of aging (which may include sarcopenia, cognitive decline, osteoporosis and others) will be the basis of Investigational New Drug (IND) applications to the FDA/CBER (Center for Biologics Evaluation and Research) for the use of mtDNA gene therapy in these conditions. By 2030, an unprecedented 20% of the population will be over age 65. Since mutations in mitochondrial DNA may be responsible for many aging phenotypes, having a therapy for mitochondrial DNA may reduce this burden. The research proposed in this Phase II STTR will directly address what aging phenotypes are caused by mitochondrial DNA and whether these phenotypes can be reversed. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
5R42AG023443-03
Application #
7282401
Study Section
Special Emphasis Panel (ZRG1-MDCN-L (10))
Program Officer
Wise, Bradley C
Project Start
2004-09-15
Project End
2009-08-31
Budget Start
2007-09-01
Budget End
2009-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$802,178
Indirect Cost
Name
Gencia Corporation
Department
Type
DUNS #
140452710
City
Charlottesville
State
VA
Country
United States
Zip Code
22903
Thomas, Ravindar R; Khan, Shaharyar M; Smigrodzki, Rafal M et al. (2012) RhTFAM treatment stimulates mitochondrial oxidative metabolism and improves memory in aged mice. Aging (Albany NY) 4:620-35
Thomas, Ravindar R; Khan, Shaharyar M; Portell, Francisco R et al. (2011) Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin. Mitochondrion 11:108-18
Young, Kisha J; Bennett, James P (2010) The mitochondrial secret(ase) of Alzheimer's disease. J Alzheimers Dis 20 Suppl 2:S381-400
Keeney, Paula M; Quigley, Caitlin K; Dunham, Lisa D et al. (2009) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20:897-907
Borland, M Kathleen; Mohanakumar, K P; Rubinstein, Jeremy D et al. (2009) Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim Biophys Acta 1792:68-74
Keeney, Paula M; Dunham, Lisa D; Quigley, Caitlin K et al. (2009) Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 220:374-82
Iyer, Shilpa; Thomas, Ravindar R; Portell, Francisco R et al. (2009) Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression. Mitochondrion 9:196-203